References
- Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266.
- Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117:1109–1120.
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
- Schnittger S, Haferlach C, Nadarajah N, et al. In AML secondary to MDS NPM1 mutations are late events, less frequent, and associated with a different pattern of molecular mutations than in de novo AML [abstract]. Blood 2014;124: (Suppl.). Abstract 700.
- Courville EL, Wu Y, Kourda J, et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 2013;26:751–761.
- Caudill JSC, Sternberg AJ, Li CY, et al. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol 2006;133:638–641.
- Ishikawa Y, Xu J, Sakashita G, et al. Abnormal cytoplasmic dyslocation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes. Leuk Lymphoma 2008;49:2359–2364.
- Ernst T, Chase A, Zoi K, et al. Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 2010;95:1473–1480.
- Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effects of point mutations in myelodyplastic syndromes. N Engl J Med 2011;364:2496–2506.
- Bains A, Luthra R, Medeiros J, et al. FLT3 and NPM1 mutations in myelodysplastic syndromes. Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011;135:62–69.
- Noguera NI, Ammatuna E, Zangrilli D, et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005;19:1479–1482.
- Ottone T, Ammatuna E, Lavorgna S, et al. An allele-specific RT-PCR assay to detect type A mutation of the mucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn 2008;10:212–216.
- Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220–2231.
- Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 2006;108:4146–4155.
- Falini B, Martelli MP, Pileri SA, et al. Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help. Haematologica 2010;95:529–534.
- Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006;108:1999–2005.
- Luo J, Qi C, Xu W, et al. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. Am J Clin Pathol 2010;133:34–40.
- Falini B, Lenze D, Hasserjian R, et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 2007;21:1566–1570.
- Konoplev S, Huang X, Drabkin AH, et al. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer 2009;115:4737–4744.
- Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from European LeukemiaNet. Blood 2013;122:2943–2964.